@article{pmid36495912,

title = {Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference},

author = {Joerg M Pollok and Pascale Tinguely and Marina Berenguer and Claus U Niemann and Dimitri A Raptis and Michael Spiro},

doi = {10.1016/S2468-1253(22)00268-0},

issn = {2468-1253},

year  = {2023},

date = {2023-01-01},

urldate = {2023-01-01},

journal = {Lancet Gastroenterol Hepatol},

volume = {8},

number = {1},

pages = {81--94},

abstract = {There is much controversy regarding enhanced recovery for recipients of liver transplants from deceased and living donors. The objectives of this Review were to summarise current knowledge on individual enhanced recovery elements on short-term outcomes, identify key components for comprehensive pathways, and create internationally accepted guidelines on enhanced recovery for liver-transplant recipients. The ERAS4OLT.org collaborative partnered by the International Liver Transplantation Society performed systematic literature reviews on the effect of 32 relevant enhanced perioperative recovery elements on short-term outcomes, and global specialists prepared expert statements on deceased and living donor liver transplantation. The Grading Recommendations, Assessment, Development and Evaluations approach was used for rating of quality of evidence and grading of recommendations. A virtual international consensus conference was held in January, 2022, in which results were presented, voted on by the audience, and discussed by an independent international jury of eight members, applying the Danish model of consensus. 273 liver transplantation specialists from 30 countries prepared expert statements on elements of enhanced recovery for liver transplantation based on the systematic literature reviews. The consensus conference yielded 80 final recommendations, covering aspects of enhanced recovery for preoperative assessment and optimisation, intraoperative surgical and anaesthetic conduct, and postoperative management for the recipients of liver transplants from both deceased and living donors, and for the living donor. The recommendations represent a comprehensive overview of the relevant elements and areas of enhanced recovery for liver transplantation. These internationally established guidelines could direct the development of enhanced recovery programmes worldwide, allowing adjustments according to local resources and practices.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Treatment of Metastatic Colorectal Cancer: ASCO Guideline},

author = {Morris, Van K. and Kennedy, Erin B. and Baxter, Nancy N. and Benson, Al B. and Cercek, Andrea and Cho, May and Ciombor, Kristen K. and Cremolini, Chiara and Davis, Anjee and Deming, Dustin A. and Fakih, Marwan G. and Gholami, Sepideh and Hong, Theodore S. and Jaiyesimi, Ishmael and Klute, Kelsey and Lieu, Christopher and Sanoff, Hanna and Strickler, John H. and White, Sarah and Willis, Jason A. and Eng, Cathy},

doi = {https://doi.org/10.1200/JCO.22.01690},

year  = {2022},

date = {2022-10-17},

journal = {Journal of Clinical Oncology},

volume = {0},

number = {0},

pages = {JCO.22.01690},

abstract = {PURPOSETo develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC).METHODSASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.RESULTSFive systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria.RECOMMENDATIONSDoublet chemotherapy should be offered, or triplet therapy may be offered to patients with previously untreated, initially unresectable mCRC, on the basis of included studies of chemotherapy in combination with anti–vascular endothelial growth factor antibodies. In the first-line setting, pembrolizumab is recommended for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumors; chemotherapy and anti–epidermal growth factor receptor therapy is recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC; chemotherapy and anti–vascular endothelial growth factor therapy is recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for patients with previously treated BRAF V600E–mutant mCRC that has progressed after at least one previous line of therapy. Cytoreductive surgery plus systemic chemotherapy may be recommended for selected patients with colorectal peritoneal metastases; however, the addition of hyperthermic intraperitoneal chemotherapy is not recommended. Stereotactic body radiation therapy may be recommended following systemic therapy for patients with oligometastases of the liver who are not considered candidates for resection. Selective internal radiation therapy is not routinely recommended for patients with unilobar or bilobar metastases of the liver. Perioperative chemotherapy or surgery alone should be offered to patients with mCRC who are candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are recommended. Qualifying statements with further details related to implementation of guideline recommendations are also included.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36089525,

title = {Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e Interventistica (SIRM), Società Italiana di Chirurgia (SIC), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part I - Cystic lesions},

author = {Maurizio Pompili and Francesco Ardito and Enrico Brunetti and Giuseppe Cabibbo and Fabrizio Calliada and Umberto Cillo and Ilario de Sio and Rita Golfieri and Mauro Grova and Salvatore Gruttadauria and Maria Guido and Massimo Iavarone and Tommaso Manciulli and Duilio Pagano and Irene Pettinari and Francesco Santopaolo and Maurizio Soresi and Agostino Colli},

doi = {10.1016/j.dld.2022.08.030},

issn = {1878-3562},

year  = {2022},

date = {2022-09-01},

urldate = {2022-09-01},

journal = {Dig Liver Dis},

abstract = {Benign liver lesions are increasingly diagnosed in daily clinical practice due to the growing use of imaging techniques for the study of the abdomen in patients who have non-specific symptoms and do not have an increased risk of hepatic malignancy. They include simple or parasitic cysts and solid benign tumors which differ widely in terms of prevalence, clinical relevance, symptoms and natural history and often lead to significant clinical problems relating to diagnosis and clinical management. Following the need to have updated guidelines on the management of benign focal liver lesions, the Scientific Societies mainly involved in their management have promoted the drafting of a new dedicated document. This document was drawn up according to the present Italian rules and methodologies necessary to produce clinical, diagnostic, and therapeutic guidelines based on evidence. Here we present the first part of the guideline, concerning the characterization of focal hepatic lesions detected by ultrasound, and the diagnosis and clinical management of simple and parasitic hepatic cysts, and of polycystic liver disease.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36089523,

title = {Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e Interventistica (SIRM), Società Italiana di Chirurgia (SIC), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part II - Solid lesions},

author = {Maurizio Pompili and Francesco Ardito and Enrico Brunetti and Giuseppe Cabibbo and Fabrizio Calliada and Umberto Cillo and Ilario de Sio and Rita Golfieri and Mauro Grova and Salvatore Gruttadauria and Maria Guido and Massimo Iavarone and Tommaso Manciulli and Duilio Pagano and Irene Pettinari and Francesco Santopaolo and Maurizio Soresi and Agostino Colli},

doi = {10.1016/j.dld.2022.08.031},

issn = {1878-3562},

year  = {2022},

date = {2022-09-01},

urldate = {2022-09-01},

journal = {Dig Liver Dis},

abstract = {Benign liver lesions are increasingly diagnosed in daily clinical practice due to the growing use of imaging techniques for the study of the abdomen in patients who have non-specific symptoms and do not have an increased risk of hepatic malignancy. They include simple or parasitic hepatic cysts and solid benign tumors which differ widely in terms of prevalence, clinical relevance, symptoms and natural history and often lead to significant clinical problems relating to diagnosis and clinical management. Following the need to have updated guidelines on the management of benign focal liver lesions, the Scientific Societies mainly involved in their management have promoted the drafting of a new dedicated document. This document was drawn up according to the present Italian rules and methodologies necessary to produce clinical, diagnostic, and therapeutic guidelines based on evidence. Here we present the second part of the guideline, concerning the diagnosis and clinical management of hemangioma, focal nodular hyperplasia, and hepatocellular adenoma.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36083140,

title = {AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma},

author = {Christopher L Bowlus and Lionel Arrivé and Annika Bergquist and Mark Deneau and Lisa Forman and Sumera I Ilyas and Keri E Lunsford and Mercedes Martinez and Gonzalo Sapisochin and Rachna Shroff and James H Tabibian and David N Assis},

doi = {10.1002/hep.32771},

issn = {1527-3350},

year  = {2022},

date = {2022-09-01},

urldate = {2022-09-01},

journal = {Hepatology},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid35975642,

title = {Revised Clinical Practice Guidelines of the Korean Pancreatobiliary Association for Acute Pancreatitis},

author = {Sang Hyub Lee and Jung Wan Choe and Young Koog Cheon and Miyoung Choi and Min Kyu Jung and Dong Kee Jang and Jung Hyun Jo and Jae Min Lee and Eui Joo Kim and Sung Yong Han and Young Hoon Choi and Hyung-Il Seo and Dong Ho Lee and Hong Sik Lee},

doi = {10.5009/gnl220108},

issn = {2005-1212},

year  = {2022},

date = {2022-08-01},

urldate = {2022-08-01},

journal = {Gut Liver},

abstract = {Acute pancreatitis can range from a mild, self-limiting disease requiring no more than supportive care, to severe disease with life-threatening complications. With the goal of providing a recommendation framework for clinicians to manage acute pancreatitis, and to contribute to improvements in national health care, the Korean Pancreatobiliary Association (KPBA) established the Korean guidelines for acute pancreatitis management in 2013. However, many challenging issues exist which often lead to differences in clinical practices. In addition, with newly obtained evidence regarding acute pancreatitis, there have been great changes in recent knowledge and information regarding this disorder. Therefore, the KPBA committee underwent an extensive revision of the guidelines. The revised guidelines were developed using the Delphi method, and the main topics of the guidelines include the following: diagnosis, severity assessment, initial treatment, nutritional support, convalescent treatment, and the treatment of local complications and necrotizing pancreatitis. Specific recommendations are presented, along with the evidence levels and recommendation grades.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Drenth2022,

title = {EASL Clinical Practice Guidelines on the management of cystic liver diseases},

author = {Joost Drenth and Thijs Barten and Hermien Hartog and Frederik Nevens and Richard Taubert and Roser Torra Balcells and Valerie Vilgrain and Tobias Böttler},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136308707&doi=10.1016%2fj.jhep.2022.06.002&partnerID=40&md5=6512ea0a342bbc506bce2aae3db9d063},

doi = {10.1016/j.jhep.2022.06.002},

issn = {01688278},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Hepatology},

publisher = {Elsevier B.V.},

abstract = {The advent of enhanced radiological imaging techniques has facilitated the diagnosis of cystic liver lesions. Concomitantly, the evidence base supporting the management of these diseases has matured over the last decades. As a result, comprehensive clinical guidance on the subject matter is warranted. These Clinical Practice Guidelines cover the diagnosis and management of hepatic cysts, mucinous cystic neoplasms of the liver, biliary hamartomas, polycystic liver disease, Caroli disease, Caroli syndrome, biliary hamartomas and peribiliary cysts. On the basis of in-depth review of the relevant literature we provide recommendations to navigate clinical dilemmas followed by supporting text. The recommendations are graded according to the Oxford Centre for Evidence-Based Medicine system and categorised as ‘weak’ or ‘strong’. We aim to provide the best available evidence to aid the clinical decision-making process in the management of patients with cystic liver disease. © 2022 European Association for the Study of the Liver},

note = {Cited by: 0; All Open Access, Bronze Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Nault2022,

title = {Benign liver tumours: understanding molecular physiology to adapt clinical management},

author = {Jean-Charles Nault and Valérie Paradis and Maxime Ronot and Jessica Zucman-Rossi},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134344871&doi=10.1038%2fs41575-022-00643-5&partnerID=40&md5=78deb8b9fa10ec5964c11e36e77eedb5},

doi = {10.1038/s41575-022-00643-5},

issn = {17595045},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Nature Reviews Gastroenterology and Hepatology},

publisher = {Nature Research},

abstract = {Improvements in understanding the pathophysiology of the different benign liver nodules have refined their nosological classification. New criteria have been identified using imaging, histology and molecular analyses for a precise diagnosis of these tumours. Improvement in the classification of liver tumours provides a more accurate prediction of disease progression and has modified patient management. Haemangioma and focal nodular hyperplasia, the most common benign liver tumours that develop in the absence of chronic liver disease, are usually easy to diagnose on imaging and do not require specific treatment. However, hepatocellular adenomas and cirrhotic macronodules can be difficult to discriminate from hepatocellular carcinoma. The molecular subtyping of hepatocellular adenomas in five major subgroups defined by HNF1A inactivation, β-catenin mutation in exon 3 or exon 7/8, and activation of inflammatory or Hedgehog pathways helps to identify the tumours at risk of malignant transformation or bleeding. New clinical, biological and molecular tools have gradually been included in diagnostic and treatment algorithms to classify benign liver tumours and improve patient management. This Review aims to explain the main pathogenic mechanisms of benign liver tumours and how this knowledge could influence clinical practice. © 2022, Springer Nature Limited.},

note = {Cited by: 0},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Wakabayashi20226,

title = {The Tokyo 2020 terminology of liver anatomy and resections: Updates of the Brisbane 2000 system},

author = {Go Wakabayashi and Daniel Cherqui and David A. Geller and Mohammed Abu Hilal and Giammauro Berardi and Ruben Ciria and Yuta Abe and Takeshi Aoki and Horacio J. Asbun and Albert C. Y. Chan and Rawisak Chanwat and Kuo-Hsin Chen and Yajin Chen and Tan To Cheung and David Fuks and Naoto Gotohda and Ho-Seong Han and Kiyoshi Hasegawa and Etsuro Hatano and Goro Honda and Osamu Itano and Yukio Iwashita and Hironori Kaneko and Yutaro Kato and Ji Hoon Kim and Rong Liu and Santiago López-Ben and Mamoru Morimoto and Kazuteru Monden and Fernando Rotellar and Yoshihiro Sakamoto and Atsushi Sugioka and Tomoharu Yoshiizumi and Keiichi Akahoshi and Felipe Alconchel and Shunichi Ariizumi and Andrea Benedetti Cacciaguerra and Manuel Durán and Alain Garcia Vazquez and Nicolas Golse and Yoshihiro Miyasaka and Yasuhisa Mori and Satoshi Ogiso and Chikara Shirata and Federico Tomassini and Takeshi Urade and Taiga Wakabayashi and Hitoe Nishino and Taizo Hibi and Norihiro Kokudo and Masayuki Ohtsuka and Daisuke Ban and Yuichi Nagakawa and Takao Ohtsuka and Minoru Tanabe and Masafumi Nakamura and Akihiko Tsuchida and Masakazu Yamamoto},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123901612&doi=10.1002%2fjhbp.1091&partnerID=40&md5=6f9e9231b8cbd8b84b02db4d4c118e4c},

doi = {10.1002/jhbp.1091},

issn = {18686974},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Hepato-Biliary-Pancreatic Sciences},

volume = {29},

number = {1},

pages = {6 – 15},

publisher = {John Wiley and Sons Inc},

abstract = {Background: The Brisbane 2000 Terminology for Liver Anatomy and Resections, based on Couinaud’s segments, did not address how to identify segmental borders and anatomic territories of less than one segment. Smaller anatomic resections including segmentectomies and subsegmentectomies, have not been well defined. The advent of minimally invasive liver resection has enhanced the possibilities of more precise resection due to a magnified view and reduced bleeding, and minimally invasive anatomic liver resection (MIALR) is becoming popular gradually. Therefore, there is a need for updating the Brisbane 2000 system, including anatomic segmentectomy or less. An online "Expert Consensus Meeting: Precision Anatomy for Minimally Invasive HBP Surgery (PAM-HBP Surgery Consensus)" was hosted on February 23, 2021. Methods: The Steering Committee invited 34 international experts from around the world. The Expert Committee (EC) selected 12 questions and two future research topics in the terminology session. The EC created seven tentative definitions and five recommendations based on the experts’ opinions and the literature review performed by the Research Committee. Two Delphi Rounds finalized those definitions and recommendations. Results: This paper presents seven definitions and five recommendations regarding anatomic segmentectomy or less. In addition, two future research topics are discussed. Conclusions: The PAM-HBP Surgery Consensus has presented the Tokyo 2020 Terminology for Liver Anatomy and Resections. The terminology has added definitions of liver anatomy and resections that were not defined in the Brisbane 2000 system. © 2021 Japanese Society of Hepato-Biliary-Pancreatic Surgery},

note = {Cited by: 6},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Marchegiani2022663,

title = {Postpancreatectomy Acute Pancreatitis (PPAP): Definition and Grading from the International Study Group for Pancreatic Surgery (ISGPS)},

author = {Giovanni Marchegiani and Savio George Barreto and Elisa Bannone and Michael Sarr and Charles M. Vollmer and Saxon Connor and Massimo Falconi and Marc G. Besselink and Roberto Salvia and Christopher L. Wolfgang and Nicholas J. Zyromski and Charles J. Yeo and Mustapha Adham and Ajith K. Siriwardena and Kyoichi Takaori and Mohammad Abu Hilal and Martin Loos and Pascal Probst and Thilo Hackert and Oliver Strobel and Olivier R. C. Busch and Keith D. Lillemoe and Yi Miao and Christopher M. Halloran and Jens Werner and Helmut Friess and Jakob R. Izbicki and Maximillian Bockhorn and Yogesh K. Vashist and Kevin Conlon and Ioannis Passas and Luca Gianotti and Marco Del Chiaro and Richard D. Schulick and Marco Montorsi and Attila Oláh and Giuseppe Kito Fusai and Alejandro Serrablo and Alessandro Zerbi and Abe Fingerhut and Roland Andersson and Robert Padbury and Christos Dervenis and John P. Neoptolemos and Claudio Bassi and Markus W. Büchler and Shailesh V. Shrikhande},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122945187&doi=10.1097%2fSLA.0000000000005226&partnerID=40&md5=adaa04de8a92f6dcf49d8dd2f6b185f6},

doi = {10.1097/SLA.0000000000005226},

issn = {00034932},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Annals of Surgery},

volume = {275},

number = {4},

pages = {663 – 672},

publisher = {Lippincott Williams and Wilkins},

abstract = {Objective:The ISGPS aimed to develop a universally accepted definition for PPAP for standardized reporting and outcome comparison.Background::PPAP is an increasingly recognized complication after partial pancreatic resections, but its incidence and clinical impact, and even its existence are variable because an internationally accepted consensus definition and grading system are lacking.Methods:The ISGPS developed a consensus definition and grading of PPAP with its members after an evidence review and after a series of discussions and multiple revisions from April 2020 to May 2021.Results:We defined PPAP as an acute inflammatory condition of the pancreatic remnant beginning within the first 3 postoperative days after a partial pancreatic resection. The diagnosis requires (1) a sustained postoperative serum hyperamylasemia (POH) greater than the institutional upper limit of normal for at least the first 48 hours postoperatively, (2) associated with clinically relevant features, and (3) radiologic alterations consistent with PPAP. Three different PPAP grades were defined based on the clinical impact: (1) grade postoperative hyperamylasemia, biochemical changes only; (2) grade B, mild or moderate complications; and (3) grade C, severe life-threatening complications.Discussions:The present definition and grading scale of PPAP, based on biochemical, radiologic, and clinical criteria, are instrumental for a better understanding of PPAP and the spectrum of postoperative complications related to this emerging entity. The current terminology will serve as a reference point for standard assessment and lend itself to developing specific treatments and prevention strategies. © 2022 Lippincott Williams and Wilkins. All rights reserved.},

note = {Cited by: 9},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ban2022161,

title = {International Expert Consensus on Precision Anatomy for minimally invasive distal pancreatectomy: PAM-HBP Surgery Project},

author = {Daisuke Ban and Hitoe Nishino and Takao Ohtsuka and Yuichi Nagakawa and Mohammed Abu Hilal and Horacio J. Asbun and Ugo Boggi and Brian K. P. Goh and Jin He and Goro Honda and Jin-Young Jang and Chang Moo Kang and Michael L. Kendrick and David A. Kooby and Rong Liu and Yoshiharu Nakamura and Kohei Nakata and Chinnusamy Palanivelu and Shailesh V. Shrikhande and Kyoichi Takaori and Chung-Ngai Tang and Shin-E Wang and Christopher L. Wolfgang and Anusak Yiengpruksawan and Yoo-Seok Yoon and Ruben Ciria and Giammauro Berardi and Giovanni Maria Garbarino and Ryota Higuchi and Naoki Ikenaga and Yoshiya Ishikawa and Shingo Kozono and Aya Maekawa and Yoshiki Murase and Yusuke Watanabe and Giuseppe Zimmitti and Filipe Kunzler and Zi-Zheng Wang and Leon Sakuma and Hiroaki Osakabe and Chie Takishita and Itaru Endo and Masao Tanaka and Hiroki Yamaue and Minoru Tanabe and Go Wakabayashi and Akihiko Tsuchida and Masafumi Nakamura},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120363013&doi=10.1002%2fjhbp.1071&partnerID=40&md5=8b0679e371c9ea9ea0ac2c31253e0768},

doi = {10.1002/jhbp.1071},

issn = {18686974},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Hepato-Biliary-Pancreatic Sciences},

volume = {29},

number = {1},

pages = {161 – 173},

publisher = {John Wiley and Sons Inc},

abstract = {Background: Surgical views with high resolution and magnification have enabled us to recognize the precise anatomical structures that can be used as landmarks during minimally invasive distal pancreatectomy (MIDP). This study aimed to validate the usefulness of anatomy-based approaches for MIDP before and during the Expert Consensus Meeting: Precision Anatomy for Minimally Invasive HBP Surgery (February 24, 2021). Methods: Twenty-five international MIDP experts developed clinical questions regarding surgical anatomy and approaches for MIDP. Studies identified via a comprehensive literature search were classified using Scottish Intercollegiate Guidelines Network methodology. Online Delphi voting was conducted after experts had drafted the recommendations, with the goal of obtaining >75% consensus. Experts discussed the revised recommendations in front of the validation committee and an international audience of 384 attendees. Finalized recommendations were made after a second round of online Delphi voting. Results: Four clinical questions were addressed, resulting in 10 recommendations. All recommendations reached at least a 75% consensus among experts. Conclusions: The expert consensus on precision anatomy for MIDP has been presented as a set of recommendations based on available evidence and expert opinions. These recommendations should guide experts and trainees in performing safe MIDP and foster its appropriate dissemination worldwide. © 2021 Japanese Society of Hepato-Biliary-Pancreatic Surgery},

note = {Cited by: 1},

keywords = {},

pubstate = {published},

tppubtype = {article}

}